- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 t ...

Century Therapeutics公司介绍 - Century Therapeutics是一家创新的生物技术公司，专注于开发诱导多能干细胞（iPSC）衍生的细胞疗法，应用于免疫肿瘤学、自身免疫和炎症性疾病[1] - 公司管理团队将参加Chardan第八届基因药物和细胞疗法制造峰会的虚拟炉边聊天和专题讨论，主题包括“iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies”[1] - Century Therapeutics利用成体干细胞的力量开发治愈性细胞疗法产品，针对癌症、自身免疫和炎症性疾病，旨在克服第一代细胞疗法的局限性，致力于开发具有潜力克服细胞疗法固有挑战的疗法，提供明显优势[2]

公司概况 - Century Therapeutics是一家专注于开发诱导多能干细胞（iPSC）衍生的细胞疗法的生物技术公司[1] - 公司管理团队将参加Chardan第八届基因药物和细胞疗法制造峰会的虚拟炉边聊天和专题讨论[1] - 事件的回放将在公司网站的“投资者”部分的“活动和演示”页面上提供，持续90天[1] 产品研发 - Century Therapeutics正在利用成年干细胞的力量开发治愈性细胞疗法产品，旨在克服第一代细胞疗法的局限性[2] - 产品候选人经过基因工程设计，专门针对血液和实体肿瘤癌症，同时也适用于自身免疫和炎症性疾病[2] - 公司致力于开发现货细胞疗法，以扩大患者的接触范围，并提供一个无与伦比的机会来推动癌症和自身免疫和炎症性疾病护理的进程[2] 联系方式 - 欲了解更多关于Century Therapeutics的信息，请访问www.centurytx.com[2] - 投资者/媒体可通过发送电子邮件至century@argotpartners.com获取更多信息[3]

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century's position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generati ...

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company's iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, synt ...

Exhibit 99.1 Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40498 Century Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2040295 (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Del ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...